VK2735 VK2735

An experimental weight-loss drug being developed in both injectable and pill forms, studied in human obesity trials. Early results show substantial weight loss competitive with other leading drugs in its class, though it remains unapproved.

Also known as Viking dual agonist

Effects Lose fat

Routes Oral Subcutaneous

Legal status Unapproved / investigational

WADA Not listed

Reported dosing

Clinical data

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose Not yet approved; trial doses being finalized

Reported range Phase II trials: injectable up to 17.5 mg once weekly; oral formulation also in development

Route Subcutaneous injection or oral (both being trialed)

Frequency Once weekly (injectable) or once daily (oral, per trial arm)

Duration Trial durations of several months

An investigational dual GIP/GLP-1 receptor agonist (Viking Therapeutics) for obesity, in both injectable and oral development tracks; not FDA-approved as of this writing.

Where this comes from Published Phase II clinical trial data (Viking Therapeutics)

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.